Hodgkin's lymphoma is a form of lymph gland cancer. Children and young adults are particularly frequently affected. Researchers at the LMU Hospital in Munich have discovered a potential new weak point in Hodgkin's lymphoma: the CD86 molecule. With the help of AI, they have developed novel immunotherapies that could be more targeted and less aggressive than previous treatments - a glimmer of hope for young patients. The study was published in the scientific journal ‘Blood’.
Around one in seven children with a malignant tumour has Hodgkin's lymphoma. The disease also frequently occurs in young adults. It is one of the cancers with the highest cure rates, with over 90 per cent of those affected surviving in the long term following aggressive, high-dose chemotherapy.
However, many of the cured children and young adults have to contend with late effects in the course of their lives. These can be minor complications, such as hormonal imbalances or an increased susceptibility to infections. But they can also be serious illnesses, such as a recurrence of cancer or heart or lung failure.
‘The need for new, less aggressive therapies that act as specifically as possible on the cancer cells and the surrounding tumour environment is therefore very great,’ says Dr Adrian Gottschlich, first author of the study. Especially as Hodgkin's lymphomas build up an environment around the actual cancer cells that suppresses any activity of the immune system against the tumour particularly strongly and ‘reprograms’ immune cells for its growth.
Researchers at LMU Hospital led by Dr Adrian Gottschlich and Prof. Dr Sebastian Kobold, both scientists in the German Consortium for Translational Cancer Research (DKTK) at the partner site in Munich, have developed new immunotherapies for patients with Hodgkin's lymphoma in the laboratory. In other words, they could attack the tumour from different angles.
The team led by the Munich physicians has created the experimental prerequisites for new targeted therapies. The focus: a molecule called CD86. ‘With the help of artificial intelligence,’ explains Prof. Sebastian Kobold, ‘we were able to identify CD86 as a central control element in the tumour environment of Hodgkin's lymphomas, which protects the cancer cells from the immune system.’
The molecule is found both on the surface of the tumour cells themselves and on the surface of certain immune cells (phagocytes) that migrate into the cancer and support its growth instead of fighting it.
In order to prevent the fatal effect of CD86, the researchers blocked the molecule in a targeted manner and were thus able to abolish the dormant state of T cells, which emphasises the central importance of CD86 in the inhibition of these immune cells. In parallel, the team developed a CAR T cell therapy against CD86. ‘These anti-CD86 CAR T cells,’ reports Gottschlich, ‘showed outstanding efficacy in numerous disease models.’
The results make CD86 a promising target structure for new therapies against Hodgkin's lymphoma in humans. The Munich scientists are already working intensively on the production of anti-CD86 CAR T cells for use in a clinical trial.
This is no easy endeavour, as it requires various components and partners as well as the necessary funds. 'What's more,' says Kobold, "our research could introduce a new generation of immune checkpoint inhibitors. These drugs could then not only reactivate the immune system - as is currently the case - but also kill the cancer cells directly."
Source: DKTK (in German)
The German Centre for Cardiovascular Research (DZHK) is funding and coordinating the German arm of a global clinical study on coronary heart disease in women. The study is part of an internationally coordinated research initiative of the Global Cardiovascular Research Funders Forum (GCRFF), in which several countries undertake to support national study components in a coordinated manner.
In this way, the GCRFF enables multinational studies that can be analysed independently of industry with full or predominantly public funding - a model that strengthens scientific independence and international cooperation equally.
The scientific management of the German study arm lies with the DZHK site in Göttingen. Prof Dr Ingo Kutschka, Director of the Clinic for Cardiothoracic and Vascular Surgery at the University Medical Centre Göttingen (UMG), and Prof Dr Bernhard Danner, Senior Physician at the same clinic, are responsible. The aim is to clarify the question of which bypass technique provides the best long-term treatment results in women, a question that has not been sufficiently researched so far.
The study is investigating the use of multiple arterial bypasses compared to standard therapy with a single arterial bypass in women with coronary heart disease. The aim is to find out whether the choice of bypass technique provides better long-term results and can reduce the risk of serious cardiovascular events such as heart attacks, strokes or repeat operations. ‘Although bypass surgery is well established, there is still a lack of comprehensive knowledge about which method provides the best long-term results, especially for women,’ says Prof Dr Ingo Kutschka, co-study leader at the UMG.
According to current studies, women with CHD have a poorer prognosis after bypass operations than men - partly because their vessels are smaller and the symptoms are often less obvious. In addition, women have long been underrepresented in clinical studies or gender-related differences have not been analysed at all. The new study only includes female patients and thus addresses a long-standing research gap.
‘The study is an excellent example of how translational research directly reaches patients - and at the same time proof of the visibility and international connectivity of the DZHK,’ says the head office of the German Centre for Cardiovascular Research.
The randomised controlled study is being conducted in ten countries worldwide. With ROMA:Women, the DZHK is sending a strong signal in favour of gender-sensitive research in cardiac medicine. In future, the results will be used to develop new guidelines specifically for the treatment of women with coronary heart disease - a long overdue step towards more personalised and fairer medicine.
Source: DZHK
Depression can affect anyone. It is common, and in many cases severe. These days, there are good treatments available, typically involving a combination of psychotherapy and medication. However, finding the right treatment can take some time. Not everyone responds equally well to every medication. Researchers at six European university medical centers, under the direction of two DZPG scientists at the Charité - Universitätsmedizin Berlin, teamed up to accelerate the process of arriving at solid findings relating to both new and known treatments. The key will be a joint study design, supported over the coming four years with more than 13 million euros (£11.7m) in funding from Wellcome.
According to the World Health Organization (WHO), severe depression is among the main drivers of the global burden of disease. Although there are many medications available to treat depression – some 30 antidepressants are approved in Germany alone – sustained improvement remains out of reach for some patients, in spite of multiple attempts using different treatment approaches. Why is that, and how can clinicians find out faster what really helps specific patients? Researchers at six member institutions of the European University Hospital Alliance (EUHA) are working together systematically in the PEARLDIVER project to find answers.
Clinical trials are the basis of evidence-based medicine. However, many of the studies performed are not meaningful enough to yield sound conclusions for clinical practice. In many cases, the available treatments are only effective for some patients, and approval of new drugs for mental health conditions lags behind that of medications for other medical fields, such as oncology, infectious disease, and neurology.
“For patients with depression who do not respond to the first treatment, there is a huge need for evidence-based, safe and effective new therapies,” explains Prof. Christian Otte, Director of the Department of Psychiatry and Neurosciences on the Charité Campus Benjamin Franklin and medical director of the large-scale European project. He has high hopes for the structured new approach: “Our platform study will significantly accelerate the development and testing of treatments for depression. At the same time, we will be able to clarify faster which of the therapies that are already available is most promising for a specific individual.”
To find the “pearls” of depression research and make new treatments available swiftly, the researchers have turned to the highly efficient platform study method. While new or existing treatment approaches have previously been evaluated in individual studies, in which patients are assigned at random to either the intervention group or a control group, a platform study relies on a shared infrastructure and shared control group to evaluate many different treatment approaches while still retaining the principle of random group assignment.
“Clinical trials are very resource-intensive. They are time-consuming and require a lot of effort. The previous practice has been to set up the entire infrastructure and all the logistics for each study fresh from the start. You could think of it as building a new stadium for every soccer game. In PEARLDIVER, we’re taking a different route. Metaphorically speaking, we’re building a big stadium together as the first step, and then all of the partners can use that infrastructure for an almost unlimited number of games – or, in our case, studies,” explains Prof. Stefan Gold, professor of clinical neuroscience at Charité and the project’s scientific director. “In addition to speeding up the process, this also makes the individual studies more meaningful and comparable.”
The goal is to build a Europe-wide research infrastructure over the next four years to allow researchers to arrive at solid findings aligned with the highest possible scientific standards in comparisons of treatment and control groups to study new and known treatment approaches. The first year will primarily focus on building the platform. Subsequently, the platform will assess the safety and efficacy of the first two new medications for depression to demonstrate the trial’s suitability and efficiency, with plans to add more treatments over time. Enrolment of participants is expected to start in 2026.
Platform studies are already successfully in use in other fields of medicine, such as oncological research. This approach is new to mental health. Another new aspect is that patients themselves played a role in designing the study as cooperation partners. The patient representative, Fanni-Laura Mäntylä, explains: “Our goal is to work together to find better solutions for how clinical trials in mental health are designed and run; how mental health treatment evolves; how to better help people with mental health challenges.” The European Patients’ Forum (EPF) is supporting the project.
Since multiple treatments can be reviewed at one and the same time, having a reusable infrastructure is extremely efficient. It represents less of a burden for study participants. Regulatory and ethical approval processes also take less time. Interim analyses permit rapid conclusions as to whether a treatment will be promising, and obviously ineffective study arms can also be discontinued quickly.
“This innovative platform study approach is very exciting because it will make testing new treatments for depression far more efficient and streamlined. It will help researchers collaborate to find answers about whether treatments are effective and for whom they would work best,” says Dr. Kim Donoghue, Senior Research Manager at Wellcome. This project to study depression, the largest Europe-wide, may also serve as a model for other mental health issues.
Source: DZPG
Infections with the hepatitis E virus often go unnoticed because they cause no symptoms. However, in patients with weakened immune systems or pre-existing liver damage, and in pregnant women, the virus can cause severe, potentially life-threatening liver inflammation. Despite existing therapeutic approaches, there are currently no authorized specific treatment options. Researchers from the German Center for Infection Research (DZIF) at TWINCORE – Centre for Experimental and Clinical Infection Research in Hannover, the Universität zu Lübeck and Heidelberg University Hospital have identified neutralizing antibodies that could be used therapeutically to prevent severe cases. The results of this research, which also involved other institutions and scientists, have been published in the journal Nature Communications.
The World Health Organization (WHO) estimates that approximately 20 million people worldwide are infected with HEV each year. Most cases are asymptomatic, but about 3.3 million develop symptomatic hepatitis, which can lead to severe chronic inflammation of the liver, including fibrosis or cirrhosis. In 2015, 44,000 people died as a result. In Germany, an estimated 400,000 people are infected each year, with some risk groups such as organ transplant recipients or people with liver damage at increased risk of severe disease.
"In our search for new therapeutic options, we examined which antibodies against the hepatitis E virus are formed in people who have survived the infection," says DZIF scientist Dr. Patrick Behrendt, Head of the Clinical Junior Research Group "Translational Virology" at TWINCORE and Senior Physician at the Department of Gastroenterology at the Hannover Medical School. To do this, they isolated so-called memory B cells from the blood of the cured patients. These are immune cells that produce antibodies. "During the more detailed characterization, we initially found that many of the antibodies were directed against the HEV capsid." This protein is a structural component of the virus that encloses its genetic information within infectious particles. However, it is also present as a soluble protein freely circulating in the blood of patients. "In this way, HEV redirects the immune response away from the infectious virus particles, thus escaping the immune response," says Behrendt.
This soluble capsid protein differs from the protein embedded in infectious viral particles by a specific modification that can potentially be used for new therapeutic approaches. "We then focused on the antibodies that specifically recognize infectious particles," says Dr. Katja Dinkelborg, a physician and researcher in Behrendt's group and one of the first authors of the publication.
Researchers at the University of Lübeck were able to decipher the exact structure and mode of action of these antibodies. Together with the team led by DZIF scientist Prof. Thomas Krey from the Institute of Biochemistry, they studied the antibodies in detail and were able to show how they bind to the virus and neutralize it. These findings are an important step towards a targeted antibody therapy against HEV. Behrendt and Krey now plan to further develop the neutralizing antibodies with antiviral activity in order to optimize them for clinical use. "Our results show that custom-designed antibodies are a promising approach to better treat hepatitis E infections," explains Krey. "With our research at the DZIF, we are laying the groundwork for future clinical trials and hope to make these antibodies available as a treatment option for at-risk groups in the near future."
Source: DZIF
The day we are born is the most dangerous day of our lives. The transition from the protected environment in the womb to independent breathing after birth can be a major challenge, particularly for premature babies. The lungs must transition from a fluid-filled organ into an air-filled system in a very short period of time - a uniquely complex process for which premature babies require medical assistance in form of positive airway pressure. Complications during this phase can have long-term health consequences.
The research project “From EAGLE to LEOPARD” by DZL researcher Vincent Gaertner, assistant doctor at the Dr. von Hauner Children's Hospital (LMU) and principal investigator at the DZL Munich site (CPC-M), starts exactly here: Dr Gaertner wants to improve our understanding how this transition works and how premature babies can be optimally supported in the delivery room. The aim is to improve medical care in this unique and critical phase of life, thereby increasing the chances of survival and the later quality of life of newborns.
The German Research Foundation (DFG) is funding this project as an Emmy Noether Junior Research Group over a period of six years.
The project has two main goals: on the one hand, the researchers want to improve our understanding of the natural adaptation of the lungs after birth, and on the other hand, they will test a new clinical strategy for supporting breathing in very prematurely born children.
In order to better understand the physiological mechanisms behind the first breaths after birth, the team will utilize a relatively novel and innovative method: electrical impedance tomography (EIT). This is a special chest belt with 32 electrodes that visualizes the air distribution in the lungs in real time. These measurements are taken immediately after birth for both full-term and preterm infants. This aims to answer the following central questions:
What’s the difference between preterm and term infants with regard to the first breaths after birth?
What’s the effect of the birth mode (cesarean section vs. natural birth) and of the time of umbilical cord clamping on the evolution of lung volumes after birth?
How do medical interventions such as ventilation or different pressure levels affect lung volumes?
The knowledge gained will be examined in a large-scale randomized clinical study. Two different pressure levels are compared for initial respiratory support of very premature children (born before the 32nd week of pregnancy) in the first ten minutes after birth. At this timepoint, the preterm lungs may benefit from a higher pressure level in order to push residual lung liquid into the interstitium and improve early lung aeration. The goal is to find out which method produces the best results. What's special: The evaluation of the success is evaluated using a novel outcome assessment which is developed together with parent representatives and which takes several outcomes into consideration and ranks them according to the perceived clinical importance to the affected families.
The project combines basic research of lung physiology with clinical application to make the start of life safer for the smallest patients.
The DFG's Emmy Noether Program gives outstandingly qualified young researchers the opportunity to qualify for a university professorship by independently leading a junior research group over a period of six years.
Source: DZL
People who do not smoke at the age of 50, have normal blood pressure, no high cholesterol levels or diabetes and maintain a healthy body weight not only live longer, but are also spared cardiovascular disease for longer. This applies equally to women and men. But even those who make changes later in life can benefit. This is what scientists from the University Medical Center Hamburg-Eppendorf (UKE) and the German Centre for Cardiovascular Research (DZHK) have discovered in a large-scale study - together with around 120 researchers worldwide. The results have now been presented at the main congress of the American College of Cardiology and published simultaneously in the New England Journal of Medicine.
‘The five classic risk factors of high blood pressure, smoking, diabetes, being underweight or overweight or obese, and high cholesterol levels are responsible for around half of all cardiovascular diseases worldwide. We wanted to know how the absence or control of these factors affects lifespan,’ says Prof Dr Christina Magnussen, first author and deputy director of the UKE's Department of Cardiology.
The study shows that women who do not have any of these risk factors at the age of 50 develop cardiovascular disease on average 13.3 years later and die 14.5 years later than women with all five risk factors. Men without these risk factors live 10.6 years longer without cardiovascular disease and die on average 11.8 years later than men with the risk factors. The risk factors themselves have different significance; for example, women who do not smoke at the age of 50 live 5.5 years longer without cardiovascular disease, compared to 4.8 years for men.
Another important result of the study: a change in behaviour is also worthwhile in later life. ‘Of all five risk factors, controlling blood pressure is associated with the most additional healthy life years,’ says Prof. Dr Stefan Blankenberg, last author of the study and Medical Director of the University Heart and Vascular Centre at the UKE. People who get their high blood pressure under control or stop smoking between the ages of 55 and 60 live longer and without cardiovascular disease than people who do not change their lifestyle.
For their study, the scientists analysed data from more than two million people from 39 countries. This makes the study one of the most comprehensive investigations to date into the influence of risk factors on life expectancy.
Original publication:
C Magnussen et al. Global effect of cardiovascular risk factors on lifetime estimates. New England Journal of Medicine 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2415879
Source: DZHK
A research team led by Prof. Henrik Semb, Director of the Institute of Translational Stem Cell Research at the DZD partner Helmholtz Munich, has gained new insights into how immature pancreatic cells decide whether to become insulin-producing beta cells or glucagon-producing alpha cells. This discovery could help advance the development of new diabetes treatments and regenerative medicine strategies.
One of the key questions in biology is how external signals guide a cell’s fate. This study shows how apical-basal polarity* plays a crucial role in determining whether immature pancreatic cells differentiate into beta cells or alpha cells, which are the main regulators of our blood sugar levels. The researchers found that changes in cell polarity influence this decision-making process.
First authors Ulf Tiemann and Chenglei Tian employed a novel human stem cell system and advanced tools like single-cell RNA sequencing and gene inactivation to identify the molecular mechanisms governing this process. They discovered that polarized immature pancreatic cells use a specific molecular pathway to increase the levels of cAMP (cyclic adenosine monophosphate), a signaling molecule that transmits external signals to regulate gene activity. More cAMP within cells inhibits the activity of a gene called ARX, which is linked to the development of alpha cells, leading to the birth of beta cells. Conversely, when cells lose their polarity, cAMP levels drop, the ARX gene remains active, and the cells are steered towards becoming alpha cells.
Applying similar analyses to other developing organs may uncover analogous or entirely new extrinsic cues that govern cell fate decisions.
“Our findings highlight how external signals influence cell identity, and similar mechanisms may be at play in other organs such as the lung, liver, and brain,” says Chenglei Tian.
Understanding how immature pancreatic cells decide whether to become beta or alpha cells opens new possibilities for diabetes therapies. By manipulating these cellular processes, the researchers demonstrated that methods to create new beta cells from stem cells can be improved, potentially leading to more effective, even curative, treatments of individuals with diabetes.
“This discovery gives us a better understanding of how we might control the development of insulin-producing beta cells, which could help in creating better treatments for diabetes,” says Henrik Semb, scientific lead of the study.
*Apical-based polarity refers to the organized structure within a cell that distinguishes its top (apical) side from its bottom (basal) side. This polarity is crucial for proper cell function and positioning.
Original publication: Pancreatic alpha and beta cell fate choice is directed by apical-basal polarity dynamics. Tiemann, U., Chenglei, T., Hermann, F. et al. Developmental Cell. 2025.
Source: DZD
Safe test procedures were developed very quickly for acute COVID-19 infections, and reliable recommendations are now available for treatment. The long-term consequences known as post-COVID, on the other hand, are still poorly understood. Due to the wide range of symptoms, this disease is difficult to diagnose and differentiate from others. In addition, post-COVID significantly restricts performance, making time-consuming examinations and frequent visits to the doctor particularly stressful for those affected. The illness therefore requires new care concepts, which are the subject of intensive research.
A research project that has now been launched aims to use smartphones and wearable fitness trackers for more precise diagnostics and more individualised patient care. "We want to develop a mobile application that can collect reliable data on physiological, behavioural and subjective complaints and make it available to the doctors treating patients," says Prof. Dr Nils Opel, explaining the aim of the research network he is coordinating. The researchers are inviting patients to participate at the post-COVID centres of the participating university hospitals and via the digital study platform Digi Hero. From their data, for example on cardiovascular function, sleep, exercise behaviour and self-reported symptoms, the research team wants to identify criteria that are characteristic of post-COVID and can support the diagnosis. Machine learning algorithms will also be used to develop models for the differential diagnosis and prediction of disease progression. The app transmits this processed data securely and in compliance with data protection regulations to the IT systems of the treating doctors for a targeted diagnosis or therapy monitoring, for example in video consultations.
The post-COVID app, which learns as it goes along, is also intended to provide users with personalised re-registration on their condition and individually tailored tips and suggestions for health-promoting behaviour such as breathing and mindfulness exercises. In a study, the researchers want to test the effectiveness of the re-registration and recommendations transmitted via the app. Nils Opel: "We are involving patient representatives, doctors' surgeries and clinical departments because the app needs to be realistic and suitable for routine care in medical practice. We see mobile monitoring via app as an opportunity to improve the current post-COVID care situation."
The research network REMIT (Remote Monitoring and Intervention for Optimised Care of Post- and Long-COVID Syndrome) is being funded by the Federal Ministry of Health with over three million euros for a period of four years as part of the research and strengthening of needs-based care for the long-term consequences of COVID-19.
Involved are:
Source: DZPG
Research data is the key to progress in health research. It enables more accurate diagnoses, personalized therapies and better care.
The eight German Centers for Health Research (DZG) have published a joint white paper: "Gesundheitsforschungsdaten: gemeinsam erschließen, effizienter forschen" (in German only).
In it, the DZG, together with the Network of University Medicine (NUM), set themselves the goal of actively shaping the national data space as important changes are taking place: The German Health Data Utilization Act (GNDG) and the European Health Data Space (EHDS) facilitate access to these data. Secure, easy access to high-quality data is especially important for AI analytics.
The DZG white paper defines the requirements for a national data space and the establishment of a research data infrastructure in Germany: easy access to data, standardization and linking of study and routine data as well as a clear legal and technical framework.
Existing platforms and infrastructures of the DZG and the NUM show the potential for synergies: they are to be expanded and linked even better.
To the white paper "Gesundheitsforschungsdaten: gemeinsam erschließen, effizienter forschen" (in German only)
To the DZG research IT working group
Every year, 10 million people contract tuberculosis (TB), a disease caused by the bacterium Mycobacterium tuberculosis (Mtb), and approximately 1.5 million patients succumb to the disease. Treatment of TB usually requires several months of antibiotic therapy, but the rise of drug-resistant forms of TB has led to an urgent need for new drugs. The novel antibiotic BTZ-043, developed jointly by researchers at the German Center for Infection Research (DZIF), the Institute for Infectious Diseases and Tropical Medicine (Tropical Institute) at the LMU University Hospital Munich and the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Leibniz-HKI) in Jena, has shown good bactericidal activity in human clinical trials. In a study recently published in the renowned journal Nature Communications, DZIF scientists led by the University of Bayreuth and the Research Center Borstel, Leibniz Lung Center—in collaboration with Leibniz-HKI, the Tropical Institute Munich and Johns Hopkins University—made important progress in the research of this drug. They were able to show that BTZ-043 effectively penetrates TB lesions and accumulates there in high concentrations. Consequently, the drug can fight Mtb bacteria even in hard-to-reach areas.
A characteristic feature of tuberculosis (tubercle = nodular swelling) is the formation of granulomas. These nodular tissue changes are formed by the body in the lungs to wall off and contain Mtb bacteria. Granulomas are composed of a fibrous capsule which surrounds a layer of immune cells and a core of dead tissue (necrotic core) where the bacteria can hide and survive. These necrotic areas pose a particular challenge as they are poorly supplied with blood, making it difficult for antibiotics to reach them. Using a mouse model that reflects the TB pathology of granuloma necrosis in humans, the DZIF research team demonstrated the remarkable ability of the new antibiotic BTZ-043 to efficiently penetrate, accumulate and reduce the bacterial load in these necrotic granulomas.
The researchers exploited an advanced mouse model in which a genetic modification causes the development of granulomas in these animals similar to those found in TB patients. In a landmark study using these mice, recently published in Nature Communications, the researchers demonstrated that the concentration of BTZ-043 in the lesions was many times higher than the minimum concentration required to effectively combat Mtb.
High-resolution MALDI mass spectrometry also revealed the unique ability of BTZ-043 to penetrate deep into the cellular compartments of the lesions and completely penetrate the necrotic centers.
"Our study represents an important step in the development of new tuberculosis antibiotics, as we were able—for the first time—to visualize the distribution of a clinical-stageTB drug under development in the granuloma," says DZIF scientist Prof. Andreas Römpp from the University of Bayreuth, Chair of Bioanalytical Sciences and Food Analysis, first author and corresponding author of the study.
"The ability of BTZ-043 to reach and act in these hard-to-reach lesions indicates a strong bactericidal effect that could make tuberculosis therapy more efficient," adds corresponding last author and DZIF scientist Dr. Kerstin Walter from the Research Center Borstel, Leibniz Lung Center.
The development of this advanced mouse model, which in contrast to many commonly used mouse models recapitulates the pathology of human tuberculosis very well, is a milestone in the search for new antibiotics against tuberculosis," adds Dr. Christoph Hölscher, research group leader at the Research Center Borstel, Leibniz Lung Center and coordinator of the central theme "New Drugs and Regimens" in the DZIF research area "Tuberculosis".
"These findings are promising for the millions of people suffering from tuberculosis worldwide and offer a glimpse of a future in which less accessible tuberculosis lesions can be reached with another drug. As research progresses, the potential of BTZ-043 to improve clinical outcomes for tuberculosis patients becomes clearer," says Dr. Julia Dreisbach, Scientific Program Manager for BTZ-043 at the Tropical Institute Munich.
The work was funded by the Federal Ministry of Education and Research (BMBF) in the framework of the German Center for Infection Research (DZIF). The researchers would like to thank their colleagues at the Research Center Borstel, Leibniz Lung Center for organizing the animal husbandry and for their support in carrying out the experiments. Further thanks go to Hapila GmbH, Gera, who produces BTZ-043 and provides all analytical standards for the LMU University Hospital Munich and Leibniz-HKI.
Original publication: Römpp, A., Treu, A., Kokesch-Himmelreich, J. et al. The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis. Nat Commun 16, 826 (2025).
Source: DZIF
Modern cancer immunotherapies are very effective, but often have severe side effects that can lead to discontinuation of therapy. Researchers at the University Medical Center Freiburg, including those from the German Cancer Consortium (DKTK), partner site Freiburg, have now shown that a special light therapy for blood cells can significantly reduce these side effects without impairing the tumor's immune response.
The so-called extracorporeal photopheresis (ECP) specifically alleviates the inflammation caused by immunotherapy. The researchers also discovered the mechanism behind it. They showed that the body's own molecule adiponectin, known from fat metabolism, regulates inflammation. The results were published in the journal Cancer Cell on February 10, 2025. The work is based on an intensive collaboration between many scientists from Freiburg, in particular the Departments of Internal Medicine I and II at the University Medical Center Freiburg, and researchers from Baltimore, USA.
“We were able to stop the side effects of cancer immunotherapy as far as possible. What is particularly exciting is that the body's defense against cancer does not suffer as a result. This significantly improves the quality of life of cancer patients,” says Prof. Dr. Robert Zeiser, Head of the Department of Tumor Immunology and Immune Regulation at the Department of Internal Medicine I at the Freiburg University Medical Center, spokesperson of the Collaborative Research Center 1479 ‘OncoEscape’ and member of the Cluster of Excellence CIBSS - Centre for Integrative Biological Signalling at the University of Freiburg. “In the future, many patients could benefit from immunotherapy for whom this has been too burdensome up to now,” says Prof. Dr. Justus Duyster, Medical Director of the Department of Internal Medicine I at the Freiburg University Medical Center.
In a clinical study with 14 patients affected by severe inflammatory side effects, ECP showed great success. 92 percent of participants reported a significant improvement in their symptoms, and all patients with inflammatory bowel disease (colitis) were completely cured. In addition, the dosage of anti-inflammatory medication such as cortisone, which often has severe side effects, was reduced in all patients.
To date, extracorporeal photopheresis has mainly been used in very specific cases in transplant medicine, for example in the treatment of graft-versus-host reactions after stem cell transplants. In this process, immune cells are removed from the patient, irradiated with UV light and returned to the body. These modified cells send out signals that calm the immune system.
Particularly surprising was the discovery that the effect of ECP is controlled by adiponectin - a molecule that was previously known primarily for its role in fat metabolism. “We were able to show that adiponectin specifically reduces pro-inflammatory cells in tissues such as the intestine without weakening the tumor defense,” says Lukas Braun, first author and molecular physician in Zeiser's research group.
“It was unexpected that a molecule from fat metabolism could influence the immune system in such a targeted way,” explains Prof. Zeiser. “This discovery could also open up new possibilities for the treatment of inflammatory diseases.”
“The ECP in combination with the knowledge about the central role of adiponectin offers new perspectives for the targeted treatment of side effects of immunotherapies,” says Zeiser. “Future studies should now confirm the results in larger patient groups and further investigate the potential of adiponectin.”
Original publication: Braun, L.M., Giesler, S., Andrieux, G. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, Volume 43, Issue 2, 269 - 291.e19.
Changes in diet and the environment constantly pose new challenges to the human metabolism. Different organs and tissues work together in complex interactions to keep the metabolism in balance. The human body has a sophisticated system of inter-organ communication that allows cells to influence metabolic pathways in distant tissues. Dysregulation of these pathways contributes to a wide range of human diseases, including obesity, diabetes, lung disease, cancer, infections, liver disease, neurodegenerative diseases, mental disorders and atherosclerosis.
Two interdisciplinary projects of the German Centers for Health Research (DZG) are investigating the complex networks and mechanisms that control the metabolism with the aim of developing new therapeutic approaches.
The human body is a highly complex network of organs and tissues that communicate, exchange signals and metabolites, and influence each other. This inter-organ communication plays a crucial role in the development and treatment of disease, but is not yet fully understood. In particular, our metabolism is closely linked to inflammation, aging and chronic disease. Metabolites can circulate as signaling molecules between tissues, either promoting healing or exacerbating disease.
A new field of research is coming into focus: inter-organ metabolomics investigates which metabolic products are exchanged between organs, how they influence biological processes and what role they play in disease mechanisms. In order to better understand these interrelationships, the German Centers for Health Research (DZG) have launched the innovation fund "Inter-Organ Metabolomics". The goal is to bring together researchers from different disciplines to gain new insights across disciplinary boundaries.
Two outstanding projects have been selected for funding and will receive a total budget of up to 766.000 euros (Project 1) and 796.000 euros (Project 2) over 2025 and 2026.
Muscle loss is not only the result of immobility or malnutrition - the immune system often plays a crucial role. Certain metabolites released in serious diseases such as cancer or COPD (chronic obstructive pulmonary disease) can permanently reprogram immune cells. Instead of regulating inflammation, they promote muscle atrophy. This may play a critical role in cachexia, a syndrome that leads to muscle wasting that cannot be fully reversed even with improved nutrition.
"Our goal is to find out which metabolites alter the immune system in a way that increases muscle loss. If we understand this, we can intervene therapeutically in a targeted way," explains Dr. Maria Rohm from Helmholtz Munich, scientist at the German Center for Diabetes Research (DZD) and head of the funded project "Metabolite-mediated epigenetic changes in immune cells induce a coordinated response across tissues in cachexia".
In addition to the immune system, fat metabolism may also play a key role in cachexia. "There are indications that adipose tissue acts as an early signal transmitter in cachexia and communicates with the muscles. If we can decipher these mechanisms, we may be able to slow down or even stop the process," says Prof. Alexander Bartelt of the Technical University of Munich and scientist at the German Center for Cardiovascular Research (DZHK).
An interdisciplinary team of researchers from five of the eight German Centers for Health Research—DZD, DZHK, DZL (lung research), DZIF (infection research) and DKTK (translational cancer research)—is investigating these mechanisms. Using cell models, disease models and patient data, the researchers are analyzing which biochemical pathways control this fatal process—in the hope of developing new therapeutic approaches to combat cachexia.
"By combining metabolomics, epigenetics and immunology, we are trying to identify the mechanism of tissue communication mediated by immune cells that leads to muscle wasting in cachexia and sarcopenia," adds DZIF scientist Prof. Karsten Hiller from the Technische Universität Braunschweig.
Cardiovascular disease, cancer, COPD and diabetes are among the most common age-related diseases. A genetic change in the blood system called clonal hematopoiesis of indeterminate potential (CHIP) may play a key role. It occurs in more than 20 percent of people over the age of 65 and is associated with chronic inflammation and impaired healing processes in the heart, lung and blood vessels.
But how exactly do these genetic changes affect the immune system and communication between organs? The second funded project, "Targeting metabolic interorgan communication in inflammation-induced aging—how somatic mutations drive age-related diseases," will investigate this question.
"We have learned that genetic mutations in blood cells not only increase the risk of leukemia, but also influence inflammatory and metabolic processes in other organs," says Prof. Michael Rieger from the Frankfurt University Hospital, scientist in the German Cancer Consortium (DKTK).
"This finding opens up completely new possibilities for fighting age-related diseases at their roots," adds DZL scientist Prof. Soni Pullamsetti from the Justus Liebig University Giessen.
The interdisciplinary team of researchers from five German Centers (DKTK, DZD, DZHK, DZIF and DZL) is investigating these questions. The goal is to decipher the effects of CHIP mutations in blood cells on inflammatory processes and metabolic changes in the affected organs. These findings could make a decisive contribution to the development of new prevention and treatment strategies against age-related diseases.
The two funded projects illustrate the following: Complex disease mechanisms can only be elucidated through interdisciplinary cooperation. Researchers from cardiovascular research, pulmonary medicine, oncology, metabolic medicine and infection research are combining their expertise to answer common questions.
The DZG Innovation Fund specifically supports cooperation across specialist and institutional boundaries—with the aim of developing new approaches to the diagnosis and treatment of widespread diseases.
Project 1: “Metabolite-mediated epigenetic changes in immune cells induce a coordinated response across tissues in cachexia.”
Scientists involved:
Maria Rohm (DZD, Helmholtz Munich), Stephan Herzig (DZD, Helmholtz Munich), Ali Önder Yildirim (DZL, Helmholtz Munich), Soni Pullamsetti (DZL, Justus Liebig University Giessen), Karsten Hiller (DZIF, Technische Universität Braunschweig), Maximilian Reichert (DKTK, TUM University Hospital), Alexander Bartelt (DZHK, Technical University of Munich)
Project 2: “Targeting the metabolic interorgan communication of ‘inflamm-aging’ – how somatic mutations drive common age-associated diseases.”
Scientists involved:
Michael Rieger (DKTK, Frankfurt University Hospital), Stefanie Dimmeler (DZHK, Goethe University Frankfurt), Soni Pullamsetti (DZL, Justus Liebig University Giessen), Triantafyllos Chavakis (DZD, Technische Universität Dresden), Christoph Spinner (DZIF, Technical University of Munich)
You are currently viewing a placeholder content from Google Maps. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from OpenStreetMap. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Mapbox. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers.
More Information